medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Original research article
Estimation of global case fatality rate of coronavirus disease 2019
(COVID-19) using meta-analyses: Comparison between calendar date
and days since the outbreak of the first confirmed case.

Ramy Abou Ghayda

Hwi Hong

1,2,‚Ä†, Keum Hwa Lee3,‚Ä†, Young Joo Han4,‚Ä† ,Seohyun Ryu5,‚Ä†, Sung

1,5,‚Ä†, Sojung Yoon5,‚Ä†, Gwang Hun Jeong6,‚Ä†, Jinhee Lee7, Jun Young Lee8, Jae

8

9

10, Andreas Kronbichler11, Marco

Won Yang , Maria Effenberger , Michael Eisenhut

Solmi

Shin

1.

12,13, Han Li14 Louis Jacob15,16, Ai Koyanagi16,17, Joaquim Radua18,19,20 and Jae Il

3,* and Lee Smith21

Department of Global Health and Population, Harvard T.H. Chan School of Public Health,
Boston, MA, USA

2.

Division of Urology, Brigham and Women's Hospital, and Harvard Medical School, Boston,
MA, USA

3.

Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea

4.

Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School
of Medicine, Changwon, Republic of Korea

5.

Yonsei University College of Medicine, Seoul, Republic of Korea

6.

College of Medicine, Gyeongsang National University, Jinju, Republic of Korea

7.

Department of Psychiatry, Yonsei University Wonju College of Medicine, Wonju, Republic
of Korea

8.

Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju, Republic
of Korea

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

9.

Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology &
Metabolism, Medical University Innsbruck, Innsbruck, Austria

10.

Luton & Dunstable University Hospital NHS Foundation Trust, Luton, United Kingdom

11.

Department of Internal Medicine IV, Nephrology and Hypertension, Medical University
Innsbruck, Innsbruck, Austria

12.

Neurosciences Department, University of Padua, Padua, Italy

13.

Padua Neuroscience Center, Padua, Italy

14.

University of Florida College of Medicine, Gainesville, FL 32610, USA

15.

Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-leBretonneux, 78180, Versailles, France.

16.

Research and Development Unit, Parc Sanitari Sant Joan de D√©u, CIBERSAM, Dr. Antoni
Pujadas, 42, Sant Boi de Llobregat, 08830, Barcelona, Spain.

17.

ICREA, Pg. Lluis Companys 23, Barcelona, Spain.

18.

Institut d'Investigacions Biom√®diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain

19.

Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience,
King's College London, London E5 8AF, UK

20.

Centre for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet,
113 30 Stockholm, Sweden

21.

The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University,
Cambridge, CB1 1PT, UK.

‚Ä† These authors contributed equally
* Correspondence: Prof. Jae Il Shin, MD, PhD
Address: Yonsei-ro 50, Seodaemun-gu, C.P.O. Box 8044, Department of Pediatrics, Yonsei
University College of Medicine, Seoul 03722, Korea
Tel.: +82-2-2228-2050; Fax: +82-2-393-9118; E-mail: shinji@yuhs.ac

Abstract:

Since the outbreak of the coronavirus disease 2019 (COVID-19) in

December of 2019 in China, the estimation of the pandemic‚Äôs case fatality rate (CFR)
has been the focus and interest of many stakeholders. In this manuscript, we prove
that the method of using the cumulative CFR is static and does not reflect the trend

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

according to the daily change per unit of time. A proportion meta-analysis was
carried out on CFR in every country reporting COVID-19 cases. Based on the results,
we performed a meta-analysis for global COVID-19 CFR. Each analysis was
performed on two different calculations of CFR: according to calendar date and
according to days since the outbreak of the first confirmed case. We thus explored an
innovative and original calculation of CFR concurrently based on the date of the first
confirmed case as well as on a daily basis. For the first time, we showed that using
meta-analyses, according to calendar date and days since the outbreak of the first
confirmed case were different. We propose that CFR according to days since the
outbreak of the first confirmed case might be a better predictor of the current CFR of
COVID-19 and its kinetics.
Keywords:

COVID-19, case fatality rate, proportion meta-analysis, calendar date,

days since first confirmed case.

1. Introduction

Since the outbreak of the coronavirus disease 2019 (COVID-19) in December of 2019
in China, COVID-19 has spread worldwide [1,2]. As of May 28 , 2020, 5,593,631
th

confirmed cases with 353,334 deaths were reported across the 216 affected countries,
territories, or areas [3]. Among other clinical and epidemiologic features of the virus,
predicting the estimates of mortality of this pandemic is crucial and indispensable.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

The estimate of the case fatality rate (CFR), is defined as the number of deaths with
COVID-19 divided by the number of confirmed COVID-19 cases. CFR has been
developed to understand the mortality and epidemiological features reporting for
emerging infectious diseases [4,5], such as Severe Acute Respiratory Syndromecoronavirus (SARS, CFR 9.6% on a global scale) [6] and Middle East Respiratory
Syndrome-coronavirus (MERS, CFR 34.5%) [7]. To date, there have been many
attempts to estimate the underlying "true CFR" of COVID-19 [8-13]. However, these
CFR are not without limitations. These estimates need to be treated with extreme
caution because each region of the world is experiencing a different stage of the
pandemic. In addition, CFR is contingent on many other factors, including the
extensiveness detection and testing efficiency, local health and pandemic response
policies, and the condition and inclusiveness of the already existing health systems.
Failure to consider these former factors and simply dividing the cumulative deaths
with COVID-19 by cumulative confirmed cases based on the latest global statistics
available will inevitably distort the CFR in each stage of COVID-19 into an unknown
direction, let alone fail to reveal the true dynamics of CFR of the disease. In addition,
several previously published papers [14,15] suggested models using CFR should be
based on the cumulative confirmed cases and deaths with a simple linear regression
analysis. However, this method of using the cumulative number is static and does
not reflect the trend according to the daily change per unit of time. Additionally, it
prevents an exact estimation of CFR because the number of the confirmed cases and

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

the onset time of the first case vary by country, and even within regions of the same
country.
Therefore, to get as close as possible to a real estimate, we calculated the CFR of
each country, concurrently based on the date of the first confirmed case as well as on
a daily basis.

2. Materials & Methods

Proportion meta-analyses were performed to obtain the average CFR for each day,
commencing from the date of the first confirmed case to the present, stratified by
each country. Therefore, we present unique CFR dynamics obtained by correcting
and theoretically circumventing the bias created by the fact that each country is
facing different stages of the pandemic. This approach to the CFR provides a new
insight that lays the foundation for a proper analysis of CFR. One caveat that we
acknowledge is that many potential positive cases that were not tested might present
possible confounding variables, skewing our results in a specific direction. At this
point, it is impossible to account for the totality of the COVID-19 cases (tested and
not tested), and this calculation is out of the scope of this study.
Global data of COVID-19 confirmed cases and deaths with COVID-19 were
collected from the European Centre for Disease Prevention and Control (ECDC,
https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases),

which

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

showed each country's data from Dec 31, 2019, to May 8, 2020. The CFR was defined
as follows:

       19
 100 %
         19
To note, our analysis of CFR included only confirmed cases by molecular or
serological testing. The data had blanks since the reports from each country were not
continuous on a daily basis, especially during the early stages of the epidemic
secondary to under-testing and under-reporting of cases. After multiple rounds of
discussions, for calculation simplicity, the blanks were decided to be processed as
the number of cases in the most recent report before the blank rather than splitting
the number of cases equally among the missing days. We stratified the confirmed
and deaths of COVID-19 for each country according to days since this country
reported its first confirmed case of COVID-19.
A proportion meta-analysis was then carried out on CFR in every country reporting
COVID-19 cases. Based on the results, we performed a meta-analysis for global
COVID-19 CFR. Each analysis was performed on two different calculations of CFR:
according to cases calendar date and according to days since the outbreak of the first
confirmed case. Every analysis was based on reports until May 8, 2020.
For a meta-analysis of the CFR of COVID-19, MedCalc version 19.2.1 software
(MedCalc Software, Ostend, Belgium, trial version) was used to analyze the
summary

effects

with

95%

confidence

interval

(CI)

and

between-study

heterogeneity. We performed a proportion meta-analysis to estimate the summary

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

effects. The summary effects obtained by the proportion meta-analysis of the CFR
under the fixed- and random-effect model for each data over time were presented as
figures, and the 95% Confidence Interval, CI, are summarized in the Supplementary
Table 1 and 2. To determine the extent of variation between the studies, we did
heterogeneity tests with Higgins' I statistic . An I value below 50% represented low
2

14

2

or moderate heterogeneity, while I >50% represented high heterogeneity [16]. For
2

graphing the patterns of CFR in all countries, Microsoft Excel version 2013 was used.

3. Results

3.1 The new dynamics of CFR revealed after the meta-analyses
Figure 1 presents the following data over time: the fixed- and the random-model
results of the meta-analysis, the pooled estimate, and the number of total cases
included in each analysis.

Figure 1. Timeline of CFR in worldwide among countries with COVID-19 reports until
Apr 17, 2020: (A) According to date and (B) According to days since 1st confirmed case
(A)

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

(B)

COVID-19: Coronavirus 2019, CFR: case fatality rate, fixed: fixed-effect model, random: random-effect model,
pooled: calculated CFR based on incidence and mortality data, N: number

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Figure 2 presents the trend of patients with COVID-19 according to date and
according to days. We obtained the time trend of CFR by calculating pooled
estimates, fixed- and random- effect estimates from meta-analyses by the calendar
date and by days since the first confirmed case

Figure 2. The trend of patients with COVID-19: (A) According to date and (B) According
to days

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

(A)

(B)

COVID-19: Coronavirus 2019, CFR: case fatality rate, No.: number, fixed: fixed-effect model, pooled: calculated
CFR based on incidence and mortality data

By comparing the figures that show the time trend of CFR stratified by the two
methods, it was visually observed that the CFRs calculated by each sorting method

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

had different trends over time: Figure 1A (CFR stratified by calendar date) vs. Figure
1B (CFR stratified by days since the first confirmed case). In both figures, results
from the random- and the fixed-effect model were almost identical; however, after
they diverge, the fixed-effect model was similar to the pooled estimates while the
random-effect model estimates were smaller. One possible explanation for the fact
that random CFR estimates were lower than the fixed estimate is that less weight is
given to countries with a small number of confirmed cases compared to countries
with a high number of cases. Namely, a higher weight is given to countries with a
large number of confirmed cases in the random estimate. On the other hand, lower
weight is given to countries with a low number of cases in the fixed estimate (Figure
3A and 3B).

Figure 3. Differences in weight between (A) Random and (B) Fixed meta-analyses to the
number of patients at one point as an example (50 countries, March 20, 2020)

(A)

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

(B)

We identified 4 distinct phases based on our results. In Figure 1A, phase 1 contains
data from January 15 to March 7, 2020, phase 2 included data from March 8 to April

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

17 and phase 3 was from April 18 to May 8. In phase 1, all CFRs ranged between 1%
and 3%. However, from March 8 to April 18 (phase 2), both fixed and pooled CFRs
increased rapidly from 3.29% to 6.43% for fixed-effect CFR and 3.40% to 7.09% for
pooled CFR. From April 18th with 2,198,764 confirmed patients to May 8th, both
fixed and pooled CFRs remained at 6%p and 7%, respectively (phase 3).
Interestingly, in phase 3, the CFR remains similar even though the number of
confirmed patients per date continues to rise after a total of 2,198,764 was reached.
Figure 2B shows a similar trend with the characteristic's phases 1 to 3, parallel to
those in Figure 1. From the day the first COVID-19 case was confirmed or Day 1 to
Day 17, the CFR ranged between 1.4 and 1.6% (phase 1). It showed an exploding
increase from Day 18 to Day 88, when the number of confirmed patients per day
reached 33,909 (phase 2). As the number of confirmed patients increased to 1,915,791
on Day 89, the fixed CFR remained at 7.45% and the pooled CFR remains at 8.21%,
despite the fact that the number of confirmed patients increased rapidly.
Importantly, in Figure 2B, an "unreliable phase" was added, which occurred after
Day 95, because the number of the confirmed cases and deaths included in the
analysis decreased significantly, due to the long-lived epidemic in only a few
countries such as China, Italy or Spain.
Comparing Figure 1A and 1B, we found that both pooled and fixed CFRs increased
approximately 1%P after adjusting the CFR standard to the days since the first
confirmed case (7.09% to 8.20%, 6.40% to 7.40%, respectively). Therefore, the CFR in

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

the plateau phase was approximately 1%P higher in the meta-analyses by days since
the first confirmed patient compared to the meta-analyses by date. This might be
explained by the "noise" in the data from the early days of the epidemic in each
country. Analogous comparison of Figure 2A and 2B revealed a similar 1%P
approximate increase in phase 3, the plateau phase, between CFR by days since the
first confirmed patient compared to the meta-analyses by date.
An additional phase emerged in Figure 1B since countries with newly emerging
COVID-19 moved to the front of onset period as they were sorted by days
(Supplementary Figure 2, see Appendix). Similarly, I value earlier reached above
2

50% representing high heterogeneity was at Day 15 and showed a plateau pattern
since Day 50 according to days (Supplementary Figure 1B) than according to
calendar date reached above 50% on February 25, 2020 and marked plateau since
April 12, 2020 (Supplementary Figure 1A, see Appendix).
Figure 1B identifies the time period of the day 15 in which the fixed- and randommodel estimates split and the estimates of fixed-model proceeds in a similar
direction to the pooled model estimates.

3.2 Correlations between the number of confirmed patients and CFR
Based on Figure 1, we also investigated the relationship between CFR and the
number of confirmed COVID-19 patients (Figure 2). Figure 2A was devised using
the number of patients according to the calendar date rather than the cumulative

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

number of patients. This figure revealed that CFRs linearly correlated with the
number of confirmed cases, the more the number of confirmed cases, the higher the
CFR. On the other hand, when the number of patients was adjusted by days since
the first confirmed case, as shown in Figure 2B, CFR increases, as shown in Figure 1,
until the number of confirmed patients per day reaches 1.0 million cases. Following
this phase, CFR then rapidly increases between 1.0 million and 1.5 million cases.
After 2.0 million cases, a plateau pattern continues.
In Figure 2B, the blurry dots represent CFRs in the "unreliable phase." In this phase,
CFR decreases when the number of confirmed patients falls below 2 million. The
unreliable phase could represent potentially a new phase, the decreasing phase. The
model according to calendar date (Figure 2A) may have underestimated the CFR,
this might be because countries being in different stages, and thus phases, of the
disease.

4. Discussion

We propose that CFR is not a fixed, static rate. It is rather dynamic, constantly
fluctuating with time, location, and population, as confirmed in Figure 1. In this
context, it is important to view CFR as a function of time, rather than presenting CFR
as a single and absolute value. Stratifying CFR by days since the first confirmed case
is a novel and innovative attempt to uncover the dynamics of CFR as the epidemic

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

unfolds itself. We believe that the CFR simply stratified by calendar date does not
reflect the true epidemic situation of each country.
Our analysis revealed a CFR trend consisting of four distinctive phases. Based on
our results, we carefully propose that the slope of epidemic model will proceed to
the next four stages as follows: phase 1 or initial phase, phase 2 or rapid increase
phase, phase 3 or plateau phase and phase 4 or decreasing phase. Based on this
statistical trend, it is estimated that the global situation of the pandemic will slow
down from the time all countries reach phase 3, and it can be improved when the
situation has reached the end of the phase. However, as mentioned above and
analyzing the data of 100 days so far, the world may remain in phase 3 as of May
2020 for an undetermined amount of time, and CFR may not have yet reached phase
4. It may take considerable amount of time to enter this final phase.
The method of calculating CFR needs to be cautioned, and its limitations
acknowledged. The numerator and the denominator of CFR should be composed of
patients infected at the same time as those who died to accurately represent the CFR.
To overcome this restraint, Baud et al.[8] and Wilson et al.[9] proposed time delayadjusted CFR to correct the delay between confirmation and death. They adjusted
the denominator of CFR as the number of confirmed cases 13-14 days before the
measured date to calculate the number of confirmed cases infected concurrently to
those who died. Based on these articles, researchers at Oxford University used their
global COVID-19 CFR model according to the date since the outbreak in Jan 2020

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

[17]. However, Oxford's calculation is also flawed since 13 to 14 days before the date
of test confirmation is not necessarily the date when a subject is infected [12].
Moreover, there are cases that show test positivity even after recovery. Additionally,
the stretching and overwhelming of the healthcare systems creates a delay between
testing and receiving the results, thus confirming the case. As this adjusted timedelay CFR leads the estimate to an unknown bias [12, 13], we used the conventional
method to calculate CFR. Moreover, the numerator of the CFR is the number of
deaths with COVID-19. We should be aware that this number is imperfect, and may
include deaths not directly caused by COVID-19, such as fatal comorbid diseases.
This may lead to an overestimation of the number relative to its true value.
In the present study, we observed unusually exaggerated estimates from our metaanalyses in the early phase (Phase 1) of the epidemic, both in CFR based on the
calendar date and days since the first confirmed case. This is thought to be a
statistical bias, as many groups and countries with small numbers were included.
The studies included in the early phase of the epidemic are mostly a bundle of data
in which deaths sporadically occurred in very small group sizes. Such data
distribution may have severely exaggerated the meta-analyses results. Therefore, we
believe that we should aim for a more standardized and homogenous analysis of the
numbers. One method would be to observe the results from the time when the
number of confirmed cases in each country has reached a certain distinct level. As a
criterion for the time when the result of the meta-analyses becomes meaningful (the

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

starting period of Phase 2), we presented the time when the fixed-effect model and
random-effect model coincided: in the time-trend graph of every meta-analysis, the
initial estimates of the random-model and the fixed-model almost coincides, and
diverges from a certain point of time which is interestingly Day 15 from the first case
in each country.
There are inevitable errors that arise because actual confirmed cases or COVID-19
deaths are not properly reflected due to differences in the medical system
capabilities and the response to the pandemic in each country. Moreover, the
number of screening tests for COVID-19 differs by the diverse screening criteria of
each country. The rapid spread of COVID-19 means there are cases and deaths that
not accounted for and consequently not recorded in the reported statistics. The
screening criteria may have changed and evolve as COVID-19 spreads in a country.
For example, South Korea had originally limited the screening tests to people with
fever (37‚àô5¬∫C or above), respiratory symptoms who had contacts with a person
returning from China or confirmed symptomatic cases within the last 14 days [18].
But as the disease spreads, South Korea widened the screening criteria to anyone
who needs to be hospitalized based on a physician's decision due to pneumonia
from an unknown source [18].
The capability and efficiency of healthcare systems and the testing ability of
COVID-19 are also important. When the overall testing capability for COVID-19 is
limited to the most severe cases hospitalized with severe illness, the number of

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

confirmed COVID-19 cases with mild symptoms and easily recoverable cases will be
underrepresented resulting in artificially inflated CFRs. The capability of healthcare
systems is central because, in practice, there are many cases where COVID-19
patients are concentrated in one geographical location. Cases of the disease in Italy
spread fast, especially in the North, with an overwhelming proportion of individuals
in need of intensive care units [19,20].
Through our meta-analysis of CFR calculated from the first confirmed case, we set
new standards for observing CFR and suggest the four phases of epidemic pattern.
From the results, it is unclear whether the CFR time trend could be explained by our
epidemic stages of COVID-19. This might be because the pandemic is still in
progress and the data is far from complete and accurate. Future studies and
discussions are needed to fulfill the unmet need for a consensus of the definition of
each phase. It would also be interesting to explore the relation between CFR and the
number of testing performed. More specifically, it would be of great added value to
explore if higher number of testing and availability is associated with a lower CFR.
When the CFR is estimated by day since the first confirmed case, the estimates could
be more representative of "the true kinetics" of COVID-19 CFR by time in a country.
The stages of the epidemic should be classified by setting appropriate standards
based on reliable global data, and discussion of setting these standards is necessary.
It is noteworthy to say that since the COVID-19 is an ongoing and unfolding

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

pandemic, we caution that the CFR time trend according to calendar days since the
first confirmed case cannot be used to predict future CFRs.

5. Conclusion

This report highlights that the CFR is not a fixed value, rather it is dynamic, and it
changes with time and population. Therefore, we strongly urge caution when
dealing with CFR values, especially in an ongoing epidemic. We originally showed
that estimation of global CFR of COVID-19, using meta-analyses of CFR, according
to the calendar date and days since the outbreak of the first confirmed case were
different. We propose that CFR according to days since the outbreak of the first
confirmed case might be a better predictor of the current CFR of COVID-19 and its
kinetics.

Conceptualization: JIS, RAG, KHL, YJH,SR, and SHH; Methodology: JIS, RAG,
KHL, YJH, SR, and SHH; Validation: JIS, RAG, KHL, YJH,SR, and SHH; Formal Analysis: JIS, RAG, KHL,
YJH,SR, and SHH; Investigation: JIS, RAG, KHL, YJH,SR, and SHH; Resources: JIS, RAG, KHL, YJH,SR, and
SHH.; Data Curation: JIS, RAG, KHL, YJH,SR, and SHH; Writing ‚Äì Original Draft Preparation: JIS, RAG, KHL,
YJH,SR, and SHH, SY,GHJ, JLL, JYL, JWY, MAE, MIE, AK, MS, HLL, LJ, AK, JR,LS.; Writing ‚Äì Review & Editing:
JIS, RAG, KHL, YJH,SR, SHH, SY,GHJ, JLL, JYL, JWY, MAE, MIE, AK, MS, HLL, LJ, AK, JR,LS; Visualization, JIS,
RAG, KHL, YJH,SR,SHH, SY,GHJ, JLL, JYL, JWY, MAE, MIE, AK, MS, HLL, LJ, AK, JR,LS Supervision: JIS, KHL,
RAG; Project Administration JIS, KHL.

Author contribution:

Funding:

This work was not supported by any agency or grant. No financial

compensation was provided to any of these individuals.

Acknowledgments:

None

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Conflicts of interest:

this research.

The authors declare no conflict of interest directly applicable to

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

References

1. World Health Organization. Coronavirus disease (COVID-19) outbreak, 2020.
https://covid19.who.int/ (accessed May 5, 2020).
2. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi,
W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China,
2019. New England Journal of Medicine. 2020, 382(8), 727‚Äì733
3.

Coronavirus

disease,

2019

(COVID-19).

Situation

Report‚Äî115.

https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200514covid-19-sitrep-115.pdf?sfvrsn=3fce8d3c_6 (accessed May 16, 2020).
4. Porta M. A dictionary of epidemiology. 5th edn.

Oxford University Press, Oxford.

(2008)
5. Battegay, M.; Kuehl, R.; Tschudin-Sutter, S.; Hirsch, H. H.; Widmer, A. F.; Neher,
R. A. 2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate ‚Äì a word
of caution. Swiss Medical Weekly. 2020. DOI: 10.1016/s1473-3099(20)30195-x.

6. Donnelly, A.; Azra, G.; Gabriel, L.; Anthony J Hedley, Christophe Fraser, Steven
Riley, Laith J Abu-Raddad, et al. ‚ÄúEpidemiological Determinants of Spread of Causal
Agent of Severe Acute Respiratory Syndrome in Hong Kong.‚Äù The

Lancet361, no.

9371 (2003): 1761‚Äì66. https://doi.org/10.1016/s0140-6736(03)13410-1.
7. Fisman, D.; Rivers, C.; Lofgren, E.; Majumder, M. S. Estimation of MERSCoronavirus Reproductive Number and Case Fatality Rate for the Spring 2014 Saudi
Arabia Outbreak: Insights from Publicly Available Data. PLoS Currents. 2014

8. Baud, D.; Qi, X.; Nielsen-Saines, K.; Musso, D.; Pomar, L.; Favre, G. Real estimates
of mortality following COVID-19 infection. The

Lancet Infectious Diseases.

2020

DOI:

10.1016/s1473-3099(20)30195-x.
9. Wilson, N.; Kvalsvig, A.; Barnard, L. T.; & Baker, M. G. Case-Fatality Risk

Estimates for COVID-19 Calculated by Using a Lag Time for Fatality. Emerging

Infectious Diseases, 2020. 26(6). doi: 10.3201/eid2606.200320

10. Rajgor, D. D.; Lee, M. H.; Archuleta, S.; Bagdasarian, N.; & Quek, S. C. The many
estimates of the COVID-19 case fatality rate. 2020. The Lancet Infectious Diseases. doi:
10.1016/s1473-3099(20)30244-9

11. Kim, D. D.; & Goel, A. Estimating case fatality rates of COVID-19. The
2020.

Infectious Diseases. doi: 10.1016/s1473-3099(20)30234-6

Lancet.

12. Spychalski, P.; B≈Ça≈ºy≈Ñska-Spychalska, A.; & Kobiela, J.; Estimating case fatality
rates of COVID-19. The
3099(20)30246-2

Lancet Infectious Diseases.

2020. doi: 10.1016/s1473-

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

13. Lipsitch M. Estimating case fatality rates of COVID-19. Lancet Infect. Dis. 2020.
doi: 10.1016/S1473-3099(20)30245-0 (2020).
14. Yang, S.; Cao, P.; Du, P.; Wu, Z.; Zhuang, Z.; Yang, L.; Yu, X.; Zhou, Q.; Feng, X.;
Wang, X.; et al. Early estimation of the case fatality rate of COVID-19 in mainland
China: a data-driven analysis. Annals of Translational Medicine2020, 8(4), 128‚Äì128
15. √ñztoprak F.; Case Fatality Rate estimation of COVID-19 for European Countries:
Turkey's Current Scenario Amidst a Global Pandemic; Comparison of Outbreaks
with European Countries. EJMO. 2020. 4, 149‚Äì159
16. Higgins JP.; Measuring inconsistency in meta-analyses. BMJ. 327, 557-560 (2003).
17. The Centre for Evidence-Based Medicine. Global Covid-19 Case Fatality Rates ‚Äì
Updated 15th May. https://www.cebm.net/covid-19/global-covid-19-case-fatalityrates/ (accessed May 17, 2020).
18.

Medicine

TKAoI.

Version

Feb

18

2020.

https://www.kaim.or.kr/bbs/index.html?code=corona&category=&gubun=&page=1&
number=12025&mode=view&keyfield=&key= (accessed Mar 20, 2020).
19. Novel Coronavirus related illness (COVID-19). Vol. 2020 (The University of
Tokyo Health Service Center, 2020).
20. Speciale, A.; Kresge, N. Virus Spread Pushes Italian Hospitals Toward Breaking
Point. Vol. 2020 (Bloomberg, 2020).

¬© 2020 by the authors. Submitted for possible open access publication under the terms
and

conditions

of

the

Creative

Commons

(http://creativecommons.org/licenses/by/4.0/).

Attribution

(CC

BY)

license

Figure 1. Timeline of CFR in worldwide among countries with COVID-19 reports until Apr 17, 2020: (A) According to date and (B) According to days since 1 confirmed
case

(A)

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Figures

st

COVID-19: Coronavirus 2019, CFR: case fatality rate, fixed: fixed-effect model, random: random-effect model, pooled: calculated CFR based on incidence and mortality data, N: number

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

(B)

(A)

(B)

COVID-19: Coronavirus 2019, CFR: case fatality rate, No.: number, fixed: fixed-effect model, pooled: calculated CFR based on incidence and mortality data

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Figure 2. The trend of patients with COVID-19: (A) According to date and (B) According to days

(A)

(B)

medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128959; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Figure 3. Differences in weight between (A) Random and (B) Fixed meta-analyses to the number of patients at one point as an example
(50 countries, March 20, 2020)

